| abstract |
The invention features a series of heterocyclic derivatives that suppress tumor necrosis factor alpha (TNF-α) -induced necroptosis. The heterocyclic compounds of the present invention are of the formulas (I) to (VIII) and compounds (I) to (I), (13) to (26), (27) to (33), (48) to (48) 57) and (58) to (70). These necrostatins are shown to suppress TNF-α induced necroptosis in FADD deficient mutants of Jurkat T cells. The present invention is further characterized by a pharmaceutical composition comprising necrostatin as a main component. The compounds and compositions of the invention can also be used to treat disorders where necrotosis appears to play a substantial role. |